Cardiovascular disease - hypertensive
Methodology & AI Transparency ⓘ
Cardiovascular disease - hypertensive Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Cardiovascular disease - hypertensive is an ICD-10-CM indexed diagnosis (I11.9) within High Blood Pressure & Vascular Health.
- 2 Real-world patient consensus: Mapped to High Blood Pressure & Vascular Health under ICD-10-CM I11.9 for Cardiovascular disease - hypertensive clinical workups.
- 3 Typical cash cost range: Clinicians assessing Cardiovascular disease - hypertensive focus on renin-angiotensin-aldosterone system upregulation [Cardiovascular disease - hypertensive I11.9] and targeted history.
- 4 Top reported side effects / signs: Longitudinal Cardiovascular disease - hypertensive monitoring tracks Serum Creatinine & in Cardiovascular disease - hypertensive (I11.9: Potassium) toward K+ 4.0 – 4.8 mEq/L (I11.9).
Ask our AI Specialists anything about Cardiovascular disease - hypertensive
What Is Cardiovascular disease - hypertensive?
Cardiovascular disease - hypertensive is an ICD-10-CM indexed diagnosis (I11.9) within High Blood Pressure & Vascular Health. Clinical evaluation centers on duplex vascular ultrasonography [Cardiovascular disease - hypertensive I11.9] alongside serial Serum Creatinine & in Cardiovascular disease - hypertensive (I11.9: Potassium) tracking (K+ 4.0 – 4.8 mEq/L (I11.9)) to guide individualized care.
Pathophysiology, Underlying Causes & Clinical Presentation
In Cardiovascular disease - hypertensive (I11.9), physiological disruption stems from renin-angiotensin-aldosterone system upregulation [Cardiovascular disease - hypertensive I11.9], informing High Blood Pressure & Vascular Health protocols that track Urine Albumin-to-Creatinine Ratio [Cardiovascular disease - hypertensive I11.9] (< 15 mg/g (I11.9)).
Common Symptoms & Clinical Signs
- • Presentation of Cardiovascular disease - hypertensive (I11.9): persistently elevated home in Cardiovascular disease - hypertensive (I11.9: or clinic blood)
- • Secondary Cardiovascular disease - hypertensive clinical sign: morning occipital headache, in Cardiovascular disease - hypertensive (I11.9: pulsatile tinnitus, or)
- • Symptom flares in Cardiovascular disease - hypertensive correlating with Serum Creatinine & in Cardiovascular disease - hypertensive (I11.9: Potassium) deviation outside K+ 4.0 – 4.8 mEq/L (I11.9)
- • Functional blood pressure impact requiring duplex vascular ultrasonography [Cardiovascular disease - hypertensive I11.9] evaluation (I11.9)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Cardiovascular disease - hypertensive Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | I11.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | High Blood Pressure & Vascular Health | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Serum Creatinine & in Cardiovascular disease - hypertensive (I11.9: Potassium) | K+ 4.0 – 4.8 mEq/L (I11.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Urine Albumin-to-Creatinine Ratio [Cardiovascular disease - hypertensive I11.9] | < 15 mg/g (I11.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Home Seated Blood in Cardiovascular disease - hypertensive (I11.9: Pressure) | < 120/75 mmHg (I11.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Cardiovascular disease - hypertensive
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Sotagliflozin Inpefa • RxCUI 2638683 | Sodium-Glucose Cotransporter 2 Inhibitor | 94% | $20.3408 | $ 185.00 /mo |
| Entresto (Sacubitril and Valsartan) Entresto • RxCUI 1656351 | Angiotensin 2 Receptor Blocker | 94% | $11.6248 | $ 6.98 /mo |
| Sacubitril and Valsartan Entresto • RxCUI 1656349 | Angiotensin 2 Receptor Blocker | 91% | $0.5265 | $ 29.82 /mo |
| Ticagrelor Brilinta • RxCUI 1116635 | P2Y12 Platelet Inhibitor | 81% | $0.2429 | $ 10.64 /mo |
| Prasugrel Effient • RxCUI 855812 | P2Y12 Platelet Inhibitor | 79% | $0.2893 | $ 8.50 /mo |
| Alirocumab Praluent • RxCUI 1659156 | PCSK9 Inhibitor | 86% | $250.5510 | $ 185.00 /mo |
| Tirofiban Aggrastat • RxCUI 1737466 | Platelet Aggregation Inhibitor | 87% | $2.9000 | $ 125.95 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Cardiovascular disease - hypertensive)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Achieved blood pressure and heart and blood vessel outcomes in high-risk: What a 8,407-Participant Study Found Mean achieved SBP less than 120 mm Hg during treatment was associated with increased risk of heart and blood vessel outcomes except for heart attack and stroke. Lancet (London, England) • 2017-06-03 • Meta-Analysis | N = 8,407 | 99/100 | PMID 28390695 ↗ |
| New Insights on Effect of Glucagon-like Peptide-1 Receptor Agonists on All-cause Mortality and: What a 21,135-Participant Study Found GLP1RA therapy when compared to placebo reduced all-cause mortality in high heart and blood vessel risk patients with type 2 diabetes. Current diabetes reviews • 2018-01-15 • Meta-Analysis | N = 21,135 | 99/100 | PMID 28413990 ↗ |
| New Insights on Heart and blood vessel outcomes of liraglutide in patients with type 2: What a 14,608-Participant Study Found Our results suggest that liraglutide treatment decreases the risk of MACE, AMI, all-cause death and heart and blood vessel death among patients with type 2 diabetes. Medicine • 2019-11-15 • Meta-Analysis | N = 14,608 | 99/100 | PMID 31725627 ↗ |
| New Insights on Association between testosterone replacement therapy and heart and blood vessel: What a 11,502-Participant Study Found Our analysis indicates that for patients with hypogonadism, testosterone replacement therapy does not increase the CVD risk and all-cause mortality. Progress in cardiovascular diseases • 2024-01-15 • Meta-Analysis | N = 11,502 | 99/100 | PMID 38589271 ↗ |
| New Insights on Heart and blood vessel and Kidney Outcomes and Mortality With Long-Acting: What a 71,351-Participant Study Found As a group, long-acting GLP-1RA, including both injectable and oral formulations, reduce incidence of MACE, HHF, and kidney events and all-cause mortality in T2D. Diabetes care • 2025-05-01 • Meta-Analysis | N = 71,351 | 99/100 | PMID 40156846 ↗ |
Cardiovascular disease - hypertensive Patient Community & “People Like Me” Threads
Filter Cardiovascular disease - hypertensive community threads and patient logs by age, biological sex, dosage, and treatment duration.